Home Newsfeeds JP Morgan Maintains Neutral on Zions Bancorp, Lowers Price Target to $62

JP Morgan Maintains Neutral on Zions Bancorp, Lowers Price Target to $62

JP Morgan analyst Steven Alexopoulos maintains Zions Bancorp (NASDAQ:ZION) with a Neutral and lowers the price target from $75 to $62.

byBenzinga Newsdesk

July 1, 2022

1 minute read

JP Morgan analyst Steven Alexopoulos maintains Zions Bancorp (NASDAQ:ZION) with a Neutral and lowers the price target from $75 to $62.

$1000 Invested In Paychex 20 Years Ago Would Be Worth This Much Today

By Benzinga Insights

August 3, 1:11 PM

Paychex (NASDAQ:PAYX) has outperformed the market over the past 20 years by 1.71% on an annualized basis producing an average annual return of 9.6%. Currently, Paychex has a market capitalization of $45.48 billion.

PAYX

Douglas Eden Discloses 7.2% Passive Stake In Hawthorn Bancshares

By Benzinga Newsdesk

December 1, 7:22 AM

https://www.sec.gov/Archives/edgar/data/893847/000149315222034066/formsc13g.htm

HWBK

OPEC+ Agrees To Maintain Current Oil Production Policy, Voices Concern About Russian Cap

By Bibhu Pattnaik

December 4, 11:53 AM

On Sunday, the OPEC and the non-OPEC producers, a group of 23 oil-producing nations known as OPEC+, decided to maintain oil production targets at current levels, including an existing policy of reducing oil production

CVX

AstraZeneca’s Asthma Treatment Scores European Approval

By Vandana Singh

September 21, 9:57 AM

The European Commission approved AstraZeneca Plc’s (NASDAQ:AZN) Tezspire (tezepelumab) as an add-on maintenance treatment for severe asthma. The approval covers patients…

AZN

JP Morgan Maintains Neutral on Zions Bancorp, Lowers Price Target to $62

Related Posts

$1000 Invested In Paychex 20 Years Ago Would Be Worth This Much Today

Douglas Eden Discloses 7.2% Passive Stake In Hawthorn Bancshares

OPEC+ Agrees To Maintain Current Oil Production Policy, Voices Concern About Russian Cap

AstraZeneca’s Asthma Treatment Scores European Approval